These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 36781853)

  • 1. Efficacy of an unmodified bivalent mRNA vaccine against SARS-CoV-2 variants in female small animal models.
    Corleis B; Hoffmann D; Rauch S; Fricke C; Roth N; Gergen J; Kovacikova K; Schlottau K; Halwe NJ; Ulrich L; Schön J; Wernike K; Widera M; Ciesek S; Mueller SO; Mettenleiter TC; Maione D; Petsch B; Beer M; Dorhoi A
    Nat Commun; 2023 Feb; 14(1):816. PubMed ID: 36781853
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A bivalent vaccine containing D614G and BA.1 spike trimer proteins or a BA.1 spike trimer protein booster shows broad neutralizing immunity.
    Du P; Li N; Xiong X; Tang S; Dai Q; Liu Z; Wang T; Gu X; Zhou Z
    J Med Virol; 2022 Sep; 94(9):4287-4293. PubMed ID: 35614524
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant in mice.
    Scheaffer SM; Lee D; Whitener B; Ying B; Wu K; Liang CY; Jani H; Martin P; Amato NJ; Avena LE; Berrueta DM; Schmidt SD; O'Dell S; Nasir A; Chuang GY; Stewart-Jones G; Koup RA; Doria-Rose NA; Carfi A; Elbashir SM; Thackray LB; Edwards DK; Diamond MS
    Nat Med; 2023 Jan; 29(1):247-257. PubMed ID: 36265510
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Persistent T cell-mediated immune responses against Omicron variants after the third COVID-19 mRNA vaccine dose.
    Belik M; Liedes O; Vara S; Haveri A; Pöysti S; Kolehmainen P; Maljanen S; Huttunen M; Reinholm A; Lundberg R; Skön M; Österlund P; Melin M; Hänninen A; Hurme A; Ivaska L; Tähtinen PA; Lempainen J; Kakkola L; Jalkanen P; Julkunen I
    Front Immunol; 2023; 14():1099246. PubMed ID: 36756112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SARS-CoV-2 Antibody Responses to the Ancestral SARS-CoV-2 Strain and Omicron BA.1 and BA.4/BA.5 Variants in Nursing Home Residents After Receipt of Bivalent COVID-19 Vaccine - Ohio and Rhode Island, September-November 2022.
    Canaday DH; Oyebanji OA; White EM; Bosch J; Nugent C; Vishnepolskiy I; Abul Y; Didion EM; Paxitzis A; Sundheimer N; Ragavapuram V; Wilk D; Keresztesy D; Cao Y; St Denis K; McConeghy KW; McDonald LC; Jernigan JA; Mylonakis E; Wilson BM; King CL; Balazs AB; Gravenstein S
    MMWR Morb Mortal Wkly Rep; 2023 Jan; 72(4):100-106. PubMed ID: 36701254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Recombinant VSV-Based Bivalent Vaccine Effectively Protects against Both SARS-CoV-2 and Influenza A Virus Infection.
    Ao Z; Ouyang MJ; Olukitibi TA; Warner B; Vendramelli R; Truong T; Meilleur C; Zhang M; Kung S; Fowke KR; Kobasa D; Yao X
    J Virol; 2022 Sep; 96(18):e0133722. PubMed ID: 36069551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SARS-CoV-2 bivalent mRNA vaccine with broad protection against variants of concern.
    Ma Q; Li M; Ma L; Zhang C; Zhang H; Zhong H; Wen J; Wang Y; Yan Z; Xiong W; Wu L; Guo J; Yang W; Yang Z; Zhang B
    Front Immunol; 2023; 14():1195299. PubMed ID: 37292197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection.
    Shi J; Zheng J; Tai W; Verma AK; Zhang X; Geng Q; Wang G; Guan X; Malisheni MM; Odle AE; Zhang W; Li F; Perlman S; Du L
    J Virol; 2022 Sep; 96(17):e0011822. PubMed ID: 35972290
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SARS-CoV-2 Omicron boosting induces de novo B cell response in humans.
    Alsoussi WB; Malladi SK; Zhou JQ; Liu Z; Ying B; Kim W; Schmitz AJ; Lei T; Horvath SC; Sturtz AJ; McIntire KM; Evavold B; Han F; Scheaffer SM; Fox IF; Mirza SF; Parra-Rodriguez L; Nachbagauer R; Nestorova B; Chalkias S; Farnsworth CW; Klebert MK; Pusic I; Strnad BS; Middleton WD; Teefey SA; Whelan SPJ; Diamond MS; Paris R; O'Halloran JA; Presti RM; Turner JS; Ellebedy AH
    Nature; 2023 May; 617(7961):592-598. PubMed ID: 37011668
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of neutralizing antibodies against SARS-CoV-2 variants by a multivalent mRNA-lipid nanoparticle vaccine encoding SARS-CoV-2/SARS-CoV Spike protein receptor-binding domains in mice.
    Zhang Q; Tiwari S; Wen J; Wang S; Wang L; Li W; Zhang L; Rawling S; Cheng Y; Jokerst J; Rana TM
    PLoS One; 2024; 19(4):e0300524. PubMed ID: 38635805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. SARS-CoV-2 mRNA vaccine induces robust specific and cross-reactive IgG and unequal neutralizing antibodies in naive and previously infected people.
    Narowski TM; Raphel K; Adams LE; Huang J; Vielot NA; Jadi R; de Silva AM; Baric RS; Lafleur JE; Premkumar L
    Cell Rep; 2022 Feb; 38(5):110336. PubMed ID: 35090596
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trivalent NDV-HXP-S Vaccine Protects against Phylogenetically Distant SARS-CoV-2 Variants of Concern in Mice.
    González-Domínguez I; Martínez JL; Slamanig S; Lemus N; Liu Y; Lai TY; Carreño JM; Singh G; Singh G; Schotsaert M; Mena I; McCroskery S; Coughlan L; Krammer F; García-Sastre A; Palese P; Sun W
    Microbiol Spectr; 2022 Jun; 10(3):e0153822. PubMed ID: 35658571
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bivalent mRNA vaccine effectiveness against SARS-CoV-2 variants of concern.
    Kumari M; Su SC; Liang KH; Lin HT; Lu YF; Chen KC; Chen WY; Wu HC
    J Biomed Sci; 2023 Jun; 30(1):46. PubMed ID: 37380988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of humoral immune responses induced by different SARS-CoV-2 spike trimers from wild-type and emerging variants with individual, sequential, and combinational delivered strategies.
    Ding C; Ni S; Zhang X; Xie J; Sun Y; He J; Mei Q; Huang L; He H; Liu Z; Gao Y
    J Med Virol; 2022 Dec; 94(12):5841-5849. PubMed ID: 35986565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neutralizing Potency of Prototype and Omicron RBD mRNA Vaccines Against Omicron Variant.
    Zang J; Yin Y; Xu S; Qiao W; Liu Q; Lavillette D; Zhang C; Wang H; Huang Z
    Front Immunol; 2022; 13():908478. PubMed ID: 35844601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of a broad-spectrum bivalent mRNA vaccine against SARS-CoV-2 variants in preclinical studies.
    Lu J; Tan S; Gu H; Liu K; Huang W; Yu Z; Lu G; Wu Z; Gao X; Zhao J; Yao Z; Yi F; Yang Y; Wang H; Hu X; Lu M; Li W; Zhou H; Yu H; Shan C; Lin J
    Emerg Microbes Infect; 2024 Dec; 13(1):2321994. PubMed ID: 38377136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elicitation of Broadly Neutralizing Antibodies against B.1.1.7, B.1.351, and B.1.617.1 SARS-CoV-2 Variants by Three Prototype Strain-Derived Recombinant Protein Vaccines.
    Yang Y; Zang J; Xu S; Zhang X; Yuan S; Wang H; Lavillette D; Zhang C; Huang Z
    Viruses; 2021 Jul; 13(8):. PubMed ID: 34452287
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccine-induced systemic and mucosal T cell immunity to SARS-CoV-2 viral variants.
    Kingstad-Bakke B; Lee W; Chandrasekar SS; Gasper DJ; Salas-Quinchucua C; Cleven T; Sullivan JA; Talaat A; Osorio JE; Suresh M
    Proc Natl Acad Sci U S A; 2022 May; 119(20):e2118312119. PubMed ID: 35561224
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety, immunogenicity and antibody persistence of a bivalent Beta-containing booster vaccine against COVID-19: a phase 2/3 trial.
    Chalkias S; Eder F; Essink B; Khetan S; Nestorova B; Feng J; Chen X; Chang Y; Zhou H; Montefiori D; Edwards DK; Girard B; Pajon R; Dutko FJ; Leav B; Walsh SR; Baden LR; Miller JM; Das R
    Nat Med; 2022 Nov; 28(11):2388-2397. PubMed ID: 36202997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Deep immunological imprinting due to the ancestral spike in the current bivalent COVID-19 vaccine.
    Wang Q; Guo Y; Tam AR; Valdez R; Gordon A; Liu L; Ho DD
    Cell Rep Med; 2023 Nov; 4(11):101258. PubMed ID: 37909042
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.